J Braun

Summary

Affiliation: Rheumazentrum Ruhrgebiet
Country: Germany

Publications

  1. pmc Synovitis in spondyloarthritides
    Heiner Appel
    Charite Berlin, Campus Benjamin Franklin, Department of Gastroenterology, Infectiology and Rheumatology, Germany
    Open Rheumatol J 5:123-6. 2011
  2. doi request reprint Optimizing the identification of patients with axial spondyloarthritis in primary care--the case for a two-step strategy combining the most relevant clinical items with HLA B27
    Annalina Braun
    Rheumazentrum Ruhrgebiet, Landgrafenstrasse 15, 44652 Herne, Germany
    Rheumatology (Oxford) 52:1418-24. 2013
  3. ncbi request reprint Gout: thoughts about a treat-to-target programme
    Juergen Braun
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Clin Exp Rheumatol 30:S142-4. 2012
  4. ncbi request reprint Axial spondyloarthritis: thoughts about nomenclature and treatment targets
    Juergen Braun
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Clin Exp Rheumatol 30:S132-5. 2012
  5. pmc Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
    Jurgen Braun
    Rheumazentrum Ruhrgebiet, Herne, Ruhr University, Bochum, Germany
    Ann Rheum Dis 71:878-84. 2012
  6. pmc Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
    Jurgen Braun
    Rheumazentrum Ruhrgebiet, Landgrafenstrasse 15, D 44652 Herne, Germany
    Ann Rheum Dis 71:661-7. 2012
  7. pmc Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
    Xenofon Baraliakos
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Arthritis Res Ther 7:R439-44. 2005
  8. pmc The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases
    Chenglong Han
    Centocor Research and Development, Inc, 200 Great Valley Parkway, Malvern, Pennsylvania 19355, USA
    Arthritis Res Ther 9:R103. 2007
  9. pmc The relationship between inflammation and new bone formation in patients with ankylosing spondylitis
    Xenofon Baraliakos
    Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Landgrafenstr, 15, 44652 Herne, Germany
    Arthritis Res Ther 10:R104. 2008
  10. pmc Expanding the armamentarium for the spondyloarthropathies
    Paul M Peloso
    University of Iowa Health Care, Department of Internal Medicine, Iowa City, IA, USA
    Arthritis Res Ther 6:S36-43. 2004

Collaborators

Detail Information

Publications96

  1. pmc Synovitis in spondyloarthritides
    Heiner Appel
    Charite Berlin, Campus Benjamin Franklin, Department of Gastroenterology, Infectiology and Rheumatology, Germany
    Open Rheumatol J 5:123-6. 2011
    ..Here, we summarize current available knowledge on synovial involvement in inflammatory processes related to SpA...
  2. doi request reprint Optimizing the identification of patients with axial spondyloarthritis in primary care--the case for a two-step strategy combining the most relevant clinical items with HLA B27
    Annalina Braun
    Rheumazentrum Ruhrgebiet, Landgrafenstrasse 15, 44652 Herne, Germany
    Rheumatology (Oxford) 52:1418-24. 2013
    ..However, whether HLA B27 contributes to that is unclear, and published recommendations have advised against it. In this study, we reanalysed data of that trial in relation to the HLA B27 results...
  3. ncbi request reprint Gout: thoughts about a treat-to-target programme
    Juergen Braun
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Clin Exp Rheumatol 30:S142-4. 2012
    ....
  4. ncbi request reprint Axial spondyloarthritis: thoughts about nomenclature and treatment targets
    Juergen Braun
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Clin Exp Rheumatol 30:S132-5. 2012
    ....
  5. pmc Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
    Jurgen Braun
    Rheumazentrum Ruhrgebiet, Herne, Ruhr University, Bochum, Germany
    Ann Rheum Dis 71:878-84. 2012
    ..To evaluate golimumab's effect on MRI-detected spinal inflammation in ankylosing spondylitis (AS)...
  6. pmc Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
    Jurgen Braun
    Rheumazentrum Ruhrgebiet, Landgrafenstrasse 15, D 44652 Herne, Germany
    Ann Rheum Dis 71:661-7. 2012
    ..To assess the efficacy and safety of golimumab over 104 weeks in patients with active ankylosing spondylitis...
  7. pmc Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
    Xenofon Baraliakos
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Arthritis Res Ther 7:R439-44. 2005
    ..Discontinuation of long-term therapy with infliximab eventually led to relapse of disease activity in all patients but one...
  8. pmc The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases
    Chenglong Han
    Centocor Research and Development, Inc, 200 Great Valley Parkway, Malvern, Pennsylvania 19355, USA
    Arthritis Res Ther 9:R103. 2007
    ..Patients in large randomized controlled studies of infliximab in RA, PsA, and AS had similar impairment in physical aspects of HRQoL at baseline and showed significantly greater improvement in HRQoL after treatment with infliximab...
  9. pmc The relationship between inflammation and new bone formation in patients with ankylosing spondylitis
    Xenofon Baraliakos
    Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Landgrafenstr, 15, 44652 Herne, Germany
    Arthritis Res Ther 10:R104. 2008
    ..Whether and how spondylitis and syndesmophyte formation are linked are unclear. Our objective was to investigate whether and how spinal inflammation are associated with new bone formation in ankylosing spondylitis...
  10. pmc Expanding the armamentarium for the spondyloarthropathies
    Paul M Peloso
    University of Iowa Health Care, Department of Internal Medicine, Iowa City, IA, USA
    Arthritis Res Ther 6:S36-43. 2004
    ..TNF antagonist therapy is well tolerated in patients with AS, with a side effect profile consistent with the prior experience of patients with RA...
  11. ncbi request reprint Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response
    J Braun
    Rheumatology Medical Center Ruhrgebiet, Herne, Germany
    Ann Rheum Dis 67:340-5. 2008
    ..There is insufficient evidence for the long-term efficacy and safety of anti-tumour necrosis factor therapy in patients with ankylosing spondylitis (AS). This is the first report on the treatment with infliximab over 5 years...
  12. ncbi request reprint [International classification of functioning, disability and health and its significance for rheumatology]
    J Braun
    Rheumazentrum Ruhrgebiet, Landgrafenstrasse 15, 44652 Herne, Deutschland
    Z Rheumatol 66:603-6, 608-10. 2007
    ....
  13. ncbi request reprint Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents
    J Braun
    Ruhr University Bochum, Germany
    Arthritis Rheum 57:639-47. 2007
    ..The purpose our study was to analyze the incidence of flares and new onset of IBD in patients with AS treated with anti-TNF agents...
  14. ncbi request reprint Ankylosing spondylitis
    Jurgen Braun
    Ruhr Universitat Bochum, Rheumazentrum Ruhrgebiet, 44652 Herne, Germany
    Lancet 369:1379-90. 2007
    ..The new treatment options with tumour necrosis factor blockers seems a breakthrough for patients refractory to conventional treatment...
  15. ncbi request reprint [Recommendations for the management of ankylosing spodylitis after ASAS/EULAR. Evaluation in the German language area]
    J Braun
    Rheumazentrum Ruhrgebiet, St Josefs Krankenhaus, Landgrafenstrasse 15, 44652, Herne, Deutschland
    Z Rheumatol 65:728-42. 2006
    ....
  16. ncbi request reprint [Spondylarthritides]
    J Braun
    Abteilung für Gastroenterologie und Rheumatologie, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin
    Z Rheumatol 65:613-31; quiz 632. 2006
    ..Patients with persistently active disease benefit from therapy with anti-TNF agents. Physiotherapy is of major importance in the general approach to patients with SpA, especially with AS...
  17. ncbi request reprint [Imaging in ankylosing spondylitis]
    J Braun
    Rheumazentrum Ruhrgebiet, Landgrafenstrasse 15, 44652 Herne
    Z Rheumatol 66:167-78. 2007
    ..MRI changes can also be quantified. New scoring methods are sensitive to change only 3 months after initiation of therapy with anti-TNF agents...
  18. ncbi request reprint Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study
    Jurgen Braun
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Arthritis Rheum 54:1646-52. 2006
    ....
  19. pmc Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial
    J Braun
    Rheumazentrum Ruhrgebiet, Landgrafenstrasse 15, 44652 Herne, Germany
    Ann Rheum Dis 65:1147-53. 2006
    ..To assess the effect of sulfasalazine (SSZ) on inflammatory back pain (IBP) due to active undifferentiated spondyloarthritis (uSpA) or ankylosing spondylitis in patients with symptom duration <5 years...
  20. ncbi request reprint [Outcome parameters for use in psoriatic arthritis]
    J Braun
    Rheumazentrum Ruhrgebiet, Herne
    Z Rheumatol 65:110, 112-8, 120-3. 2006
    ..In addition, functional impairments, quality of life and parameters concerned with work must be considered. There are hardly any measuring instruments specific to PsA; many have been developed and used primarily for SpA or RA...
  21. ncbi request reprint Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides
    J Braun
    Rheumazentrum Ruhrgebiet, Herne and University Medicine Berlin, Campus Benjamin Franklin, Berlin, Germany
    Scand J Rheumatol 34:178-90. 2005
    ..However, severe infections, including tuberculosis, have been reported. These can be largely prevented by appropriate screening. The benefits of anti-TNF therapy in AS seem to outweigh these shortcomings...
  22. pmc First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis
    J Braun
    Rheumazentrum Ruhrgebiet, Landgrafenstr 15, 44652 Herne, Germany
    Ann Rheum Dis 65:316-20. 2006
    ..To update the international recommendations for use of anti-tumour necrosis factor (TNF) agents in the treatment of ankylosing spondylitis...
  23. doi request reprint Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial
    J Braun
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Arthritis Rheum 58:73-81. 2008
    ..To compare the efficacy and safety of subcutaneous (SC) versus oral administration of methotrexate (MTX) in patients with active rheumatoid arthritis (RA)...
  24. doi request reprint Canadian recommendations for the management of spondyloarthritis address many different levels of patient care
    Jurgen Braun
    Rheumazentrum Ruhrgebiet, Landgrafenstr 15, 44652 Herne, Germany
    Nat Clin Pract Rheumatol 4:234-5. 2008
  25. doi request reprint [Further education: a core responsibility of the German Society for Rheumatology and the Rheuma Academy]
    J Braun
    Rheumazentrum Ruhrgebiet, Landgrafenstr 15, 44652, Herne, Deutschland
    Z Rheumatol 70:701-11. 2011
    ..Many of the projects are dependent on financial support especially by industry. In this article the most important theses and arguments from the individual lectures will be presented...
  26. pmc Identifying patients with axial spondyloarthritis in primary care: how useful are items indicative of inflammatory back pain?
    A Braun
    Rheumazentrum Ruhrgebiet, Landgrafenstr 15, 44652 Herne, Germany
    Ann Rheum Dis 70:1782-7. 2011
    ..The value of clinical items defining inflammatory back pain to identify patients with axial spondyloarthritis (SpA) in primary care is unclear...
  27. doi request reprint Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome
    Xenofon Baraliakos
    Rheumazentrum Ruhrgebiet, Ruhr University Bochum, Landgrafenstr 15, 44652 Herne, Germany
    Rheumatology (Oxford) 50:1690-9. 2011
    ..To report for the first time on the efficacy and safety of anti-TNF therapy after 8 years of follow-up in patients with active AS, and analyse possible short-term predictors for long-term clinical outcomes...
  28. doi request reprint [Spondyloarthritides]
    J Braun
    Rheumazentrum Ruhrgebiet, Ruhr Universitat Bochum, Landgrafenstrasse 15, Herne, Germany
    Internist (Berl) 52:657-70. 2011
    ..New criteria for classification of axial and peripheral spondyloarthritis have recently become available and international recommendations for the management of ankylosing spondylitis were recently published...
  29. pmc 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
    J Braun
    Rheumazentrum Ruhrgebiet, Landgrafenstrasse 15, 44652 Herne, Germany
    Ann Rheum Dis 70:896-904. 2011
    ..There are now 11 bullet points including 2 new ones, one related to extra-articular manifestations and one to changes in the disease course. With a mean score of 9.1 (range 8-10) the SOR was generally very good...
  30. ncbi request reprint Optimal administration and dosage of methotrexate
    J Braun
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Clin Exp Rheumatol 28:S46-51. 2010
    ..Although this result does not mean that every patient will be in need of parenteral administration of MTX, it suggests that very active patients and those with a worse prognosis may have more benefit from this strategy...
  31. doi request reprint Clinical significance of inflammatory back pain for diagnosis and screening of patients with axial spondyloarthritis
    Juergen Braun
    Correspondence to Professor Juergen Braun, Rheumazentrum Ruhrgebiet, Herne D 44652, Germany
    Ann Rheum Dis 69:1264-8. 2010
    ..The value of IBP for diagnosis of SpA increases in the presence of other more or less sensitive and specific features of SpA such as response to exercise and physical therapy and/or treatment with non-steroidal anti-inflammatory agents...
  32. doi request reprint [Spondyloarthritides]
    J Braun
    St Josefs Krankenhaus, Rheumazentrum Ruhrgebiet, Ruhr Universitat Bochum, Landgrafenstrasse 15, Herne, Germany
    Z Rheumatol 69:425-32; quiz 433-4. 2010
    ..The new ASAS classification criteria have helped to improve the early diagnosis of SpA, with MRI and early HLA B27 determination playing an important role...
  33. doi request reprint Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis
    Jurgen Braun
    Rheumazentrum Ruhrgebiet and Ruhr University Bochum, Bochum, Germany
    Rheumatology (Oxford) 49:1578-89. 2010
    ..To compare the clinical manifestations of spinal disease, peripheral arthritis and enthesitis, and to evaluate the effectiveness of adalimumab in a large cohort of patients with AS in relation to the presence or absence of psoriasis...
  34. ncbi request reprint [Osteoporosis diagnosis and therapy according to the 2010 guidelines]
    J Braun
    Rheumazentrum Ruhrgebiet, Landgrafenstr 15, 44652, Herne, Deutschland
    Z Rheumatol 69:327-39. 2010
    ..The German guideline recommends that a specific long-term osteoporosis medication be initiated in individuals with a 30% 10-year risk for hip fractures and vertebral fractures...
  35. ncbi request reprint Biologics in the treatment of rheumatoid arthritis and ankylosing spondylitis
    J Braun
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Clin Exp Rheumatol 27:S164-7. 2009
    ..There are some differences between the agents.Whether the recent developments of targeted therapies in RA with agents such as rituximab, abatacept and tocilizumab will also work for AS is unknown at present...
  36. doi request reprint Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab
    Jurgen Braun
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Arthritis Rheum 61:1032-6. 2009
    ..This post hoc analysis of a large, randomized, placebo-controlled trial examined the effect of infliximab on hemoglobin levels, physical function, and fatigue in patients with AS...
  37. doi request reprint [Ankylosing spondylitis. Target treatment criteria]
    J Braun
    Rheumazentrum Ruhrgebiet, Landgrafenstr 15, 44652, Herne
    Z Rheumatol 68:30-6. 2009
    ....
  38. doi request reprint Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period
    Jurgen Braun
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Arthritis Rheum 59:1270-8. 2008
    ..To assess safety and efficacy of infliximab in patients with ankylosing spondylitis (AS) through 102 weeks...
  39. ncbi request reprint Therapy of ankylosing spondylitis--a review. Part I: Conventional medical treatment and surgical therapy
    J Braun
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Scand J Rheumatol 34:97-108. 2005
    ..AS-specific problems are spinal fractures and atlantoaxial instability, which need careful management including surgery. Joint replacement therapy is established and beneficial for AS-disturbed joints of the hip and knee...
  40. ncbi request reprint Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides
    Juergen Braun
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Expert Opin Investig Drugs 12:1097-109. 2003
    ..Tuberculosis can be mostly prevented if patients are checked for previous contact with tuberculosis. Currently, the benefits of anti-TNF therapy in AS seem to outweigh these shortcomings...
  41. ncbi request reprint Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system
    J Braun
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Arthritis Rheum 48:1126-36. 2003
    ....
  42. ncbi request reprint Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases
    Jurgen Braun
    Rheumazentrum Ruhrgebiet, Landgrafenstr 15, 44652 Herne, Germany
    Expert Opin Biol Ther 3:141-68. 2003
    ..Many clinical trials in these diseases have demonstrated that biological therapy with mAbs directed against TNF-alpha is effective and relatively safe...
  43. ncbi request reprint [Glucocorticoid-induced osteoporosis]
    J Braun
    Rheumazentrum Ruhrgebiet, Landgrafenstrasse 15, 44652 Herne
    Orthopade 30:444-50. 2001
    ..Efforts should be intensified to ensure even more consistent application in daily practice. Doctors should treat their steroid patients on the basis of the clear-cut indications for intervention despite budget problems...
  44. pmc Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis
    J Braun
    Rheumazentrum Ruhrgebiet, Landgrafenstrasse 15, 44652 Herne, Germany
    Ann Rheum Dis 64:229-34. 2005
    ....
  45. ncbi request reprint New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy
    J Braun
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Curr Opin Rheumatol 13:245-9. 2001
    ..Infliximab is approved for the treatment of Crohn disease. In addition, there are now also positive data for infliximab in the treatment of ankylosing spondylitis and for etanercept and infliximab in the treatment of psoriatic arthritis...
  46. ncbi request reprint Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept
    Jan Brandt
    Department of Gastroenterology Rheumatology, Benjamin Franklin Hospital, Free University FU Berlin, Germany
    J Rheumatol 31:531-8. 2004
    ..In this open study we examined the efficacy of the TNF-alpha receptor fusion protein etanercept in patients with uSpA...
  47. doi request reprint Imaging of axial spondyloarthritis including ankylosing spondylitis
    J Braun
    Rheumazentrum Ruhrgebiet, Landgrafenstr 15, 44652 Herne, Germany
    Ann Rheum Dis 70:i97-103. 2011
    ..Low sclerostin and DKK-1 serum levels, both inhibitors of bone formation, were found to be associated with syndesmophyte formation in patients with AS...
  48. ncbi request reprint Biological therapies in the spondyloarthritides--the current state
    J Braun
    Rheumazentrum Ruhrgebiet, Landgrafenstrasse 15, 44652 Herne, Germany
    Rheumatology (Oxford) 43:1072-84. 2004
    ..Complicated infections including tuberculosis have been reported. These can largely be prevented by appropriate screening. As it stands now, the benefits of anti-TNF therapy in AS seem to outweigh these shortcomings...
  49. pmc Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems
    J Braun
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Ann Rheum Dis 63:1046-55. 2004
    ..To compare conventional radiography and magnetic resonance imaging (MRI) for detection of chronic changes in the spine of patients with ankylosing spondylitis (AS)...
  50. ncbi request reprint Biologic therapies in the spondyloarthritis: new opportunities, new challenges
    Juergen Braun
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Curr Opin Rheumatol 15:394-407. 2003
    ..These can be largely prevented by appropriate screening. At it stands now, the benefits of antitumor necrosis factor therapy in ankylosing spondylitis seem to outweigh these shortcomings...
  51. ncbi request reprint Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years
    J Braun
    Rheumatology Medical Center, Ruhrgebeit, Herne, Ruhr University, Bochum, Germany
    Rheumatology (Oxford) 44:670-6. 2005
    ..This report provides analyses from a 3-yr extension study, as a follow-up to both the 1- and 2-yr open label extensions of the original 3-month randomized controlled trial of infliximab in patients with AS...
  52. pmc Building consensus on nomenclature and disease classification for ankylosing spondylitis: results and discussion of a questionnaire prepared for the International Workshop on New Treatment Strategies in Ankylosing Spondylitis, Berlin, Germany, 18-19 Janua
    J Braun
    Rheumazentrum Ruhrgebiet, Landgrafenstrasse 15, 44652 Herne, Germany
    Ann Rheum Dis 61:iii61-7. 2002
    ..There is currently no universal consensus on nomenclature for spondyloarthropathy (SpA), or on activity and severity criteria for ankylosing spondylitis (AS)...
  53. pmc Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches
    Juergen Braun
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Arthritis Res 4:307-21. 2002
    ..However, it remains to be shown whether patients benefit from long-term treatment, whether radiological progression and ankylosis can be stopped and whether long-term biologic therapy is safe...
  54. pmc Staging of patients with ankylosing spondylitis: a preliminary proposal
    J Braun
    Rheumazentrum Ruhrgebiet, Landgrafenstrasse 15, 44652 Herne, Germany
    Ann Rheum Dis 61:iii9-23. 2002
    ..The proposed system needs to be evaluated closely and amended as needed to assure its usefulness in clinical and research settings...
  55. ncbi request reprint Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept
    J Braun
    Rheumazentrum Ruhrgebiet, and Ruhr University Bochum, Herne, Germany
    Arthritis Rheum 52:2447-51. 2005
    ..To estimate the incidence of anterior uveitis in patients with ankylosing spondylitis (AS) who underwent anti-tumor necrosis factor (anti-TNF) therapy, using data from recently performed trials...
  56. ncbi request reprint [Treatment of ankylosing spondylitis and undifferentiated spondyloarthritis with TNF alpha-antagonists]
    J Brandt
    Rheumazentrum Ruhrgebiet, Landgrafenstr 15, 44652 Herne, Germany
    Z Rheumatol 62:218-27. 2003
    ..In expectation of the approval of infliximab and etanercept for the treatment of active AS international guidelines for initiation, monitoring and discontinuation of these agents have been recently proposed...
  57. ncbi request reprint Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial
    J Braun
    Benjamin Franklin Hospital, Free University, Berlin, Germany
    Arthritis Rheum 48:2224-33. 2003
    ..The purpose of this study was to evaluate the efficacy and safety of infliximab treatment of AS for a 1-year period...
  58. pmc Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience
    J Braun
    Rheumazentrum Ruhrgebiet, Landgrafenstrasse 15, 44652 Herne, Germany
    Ann Rheum Dis 61:iii51-60. 2002
    ..Together, these findings herald an age of more effective treatment of patients with AS with anti-TNFalpha and other emerging biological agents...
  59. ncbi request reprint Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis
    J Brandt
    Benjamin Franklin Hospital, Free University Berlin, Berlin, Germany
    Arthritis Rheum 48:1667-75. 2003
    ..This study was designed to investigate the efficacy of anti-TNFalpha therapy with etanercept, a 75-kd receptor fusion protein, in active AS...
  60. pmc Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept
    M Rudwaleit
    Rheumatology, Charite Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 64:1305-10. 2005
    ....
  61. pmc Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging
    X Baraliakos
    Rheumazentrum Ruhrgebiet, Landgrafenstr 15, 44652 Herne, Germany
    Ann Rheum Dis 64:730-4. 2005
    ..Magnetic resonance imaging (MRI) is increasingly used to detect inflammation in the spine of patients with ankylosing spondylitis (AS)...
  62. ncbi request reprint Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept
    X Baraliakos
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Arthritis Rheum 52:1216-23. 2005
    ..To assess spinal inflammation by magnetic resonance imaging (MRI) before and after treatment with the tumor necrosis factor receptor fusion protein etanercept compared with placebo...
  63. pmc Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept
    J Zou
    Rheumatology, Benjamin Franklin Klinikum, Deutsches Rheumaforschungszentrum, Berlin, Germany
    Ann Rheum Dis 62:561-4. 2003
    ..The precise mechanism of action, however, is not known...
  64. doi request reprint The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal
    M Rudwaleit
    Med Klinik I, Charite, Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 68:770-6. 2009
    ..The objective of this study was to develop candidate classification criteria for axial SpA that include patients with but also without radiographic sacroiliitis...
  65. ncbi request reprint Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial
    J Braun
    Department of Rheumatology, Benjamin Franklin Hospital, Free University of Berlin, Berlin, Germany
    Lancet 359:1187-93. 2002
    ..BACKGROUND Treatment options for patients with ankylosing spondylitis are few. We aimed to assess the effectiveness of infliximab, an antibody to tumour necrosis factor (TNF)-alpha, in treatment of such patients...
  66. pmc Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis
    M Rudwaleit
    Rheumatology, Department of Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 63:665-70. 2004
    ..TNFalpha blockers have been shown to be highly efficacious in patients with active ankylosing spondylitis (AS)...
  67. ncbi request reprint Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab
    X Baraliakos
    Rheumazentrum Ruhrgebiet, Herne, Ruhr University Bochum, Germany
    Rheumatology (Oxford) 46:1450-3. 2007
    ..The objective of this article was to study the effect of infliximab on structural changes in AS over 4 yrs...
  68. ncbi request reprint Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data
    X Baraliakos
    Rheumazentrum Ruhrgebiet, Herne, Ruhr University Bochum, Bochum, Germany
    Arthritis Rheum 53:856-63. 2005
    ....
  69. ncbi request reprint MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis
    M Rudwaleit
    Medizinische Klinik I, Campus Benjamin Franklin, Charite Medical School Berlin, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Rheum Dis 67:1276-81. 2008
    ..To evaluate the role of MRI in predicting a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) improvement of at least 50% (BASDAI 50) upon anti-tumour necrosis factor (TNF) therapy of active ankylosing spondylitis (AS)...
  70. pmc Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences
    X Baraliakos
    Rheumazentrum Ruhrgebiet, Herne, Ruhr University Bochum, Germany
    Ann Rheum Dis 64:1141-4. 2005
    ....
  71. pmc Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab
    X Baraliakos
    Rheumazentrum Ruhrgebiet, Herne, Ruhr University Bochum, Germany
    Ann Rheum Dis 64:1462-6. 2005
    ..It is unclear whether anti-TNF treatment affects chronic spinal changes in AS...
  72. ncbi request reprint Treatment of rheumatoid arthritis and ankylosing spondylitis
    J Braun
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Clin Exp Rheumatol 27:S146-7. 2009
    ..In AS, NSAIDs, potentially especially coxibs, may even prevent new bone formation due to their inhibitory effect on cyclooxygenase-2...
  73. ncbi request reprint Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly
    J Braun
    Rheumatology Medical Cener, Ruhrgebeit, Herne, Ruhr University, Bochum, Germany
    Rheumatology (Oxford) 46:999-1004. 2007
    ....
  74. pmc New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy
    J Sieper
    Medical Department I, Rheumatology, University Hospital Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 60:iii58-61. 2001
    ..Allergy, lupus-like diseases, and tuberculosis are rare side effects which need to be considered. At first glance, the possible benefits of anti-TNFalpha treatment seem to outweigh these shortcomings, including the high cost...
  75. ncbi request reprint Perioperative use of methotrexate
    F Heldmann
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Clin Exp Rheumatol 28:S110-3. 2010
    ..There is some evidence that treatment with MTX is safe prior to and after elective surgical procedures. Importantly, disease activity is better controlled when MTX is not interrupted from weekly administration...
  76. pmc International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis
    J Braun
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Ann Rheum Dis 62:817-24. 2003
    ..To obtain an international consensus about the use of anti-tumour necrosis factor alpha (anti-TNF alpha) for treating patients with ankylosing spondylitis (AS)...
  77. ncbi request reprint [Patient evaluation of the German version of the ASAS/EULAR recommendations for the management of ankylosing spondylitis]
    U Kiltz
    Rheumazentrum Ruhrgebiet, St Josefs Krankenhaus, Landgrafenstr 15, 44652, Herne, Deutschland
    Z Rheumatol 67:694-700, 702. 2008
    ..The present translation met with broad approval. To minimize text comprehension problems, patients should be involved in compiling a future patient version...
  78. pmc Six months open label trial of leflunomide in active ankylosing spondylitis
    H Haibel
    Medical Department I, Rheumatology, Charite, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Rheum Dis 64:124-6. 2005
    ..To examine the potential therapeutic effects of leflunomide in patients with active AS in an open label study...
  79. ncbi request reprint [Ankylosing spondylitis--current state of imaging including scoring methods]
    C E Althoff
    Institut fur Radiologie, Charite Universitatsmedizin Berlin, Charite Campus Mitte, Schumannstrasse 20 21, 10117, Berlin, Deutschland
    Z Rheumatol 65:688-99. 2006
    ..This review article presents the imaging modalities used in AS patients, typical findings, and relevant methods of analysis. The most recent developments are discussed...
  80. ncbi request reprint Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers
    A Zink
    German Rheumatism Research Center, Department of Internal Medicine, Klinikum Benjamin Franklin, Berlin, Free University
    J Rheumatol 27:613-22. 2000
    ....
  81. pmc Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis
    J Zochling
    Rheumazentrum Ruhrgebiet, St Josefs Krankenhaus, Landgrafenstr 15, 44652 Herne, Germany
    Ann Rheum Dis 65:423-32. 2006
    ..To assess available management strategies in ankylosing spondylitis (AS) using a systematic approach, as a part of the development of evidence based recommendations for the management of AS...
  82. ncbi request reprint Assessment of ankylosing spondylitis
    J Zochling
    St Josefs Krankenhaus, Landgrafenstr 15, 44652 Herne, Germany
    Clin Exp Rheumatol 23:S133-41. 2005
    ..In clinical trials, the assessment of disease response to therapy using the ASAS Response Criteria is a valuable means of determining treatment efficacy and allows comparison of response across trials and interventions...
  83. ncbi request reprint Immunological basis for the use of TNFalpha-blocking agents in ankylosing spondylitis and immunological changes during treatment
    J X Zou
    Department of Rheumatology, Klinikum Benjamin Franklin, Free University, Berlin, Germany
    Clin Exp Rheumatol 20:S34-7. 2002
    ..While infliximab induced a downregulation of the production of the T-helper 1-cytokines IFNgamma and TNFalpha, etanercept treatment triggered rather an upregulation of these cytokines secreted by T cells after in vitro stimulation...
  84. ncbi request reprint Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab
    J Sieper
    Department of Rheumatology, Charite Medical School, Campus Benjamin Franklin, Berlin, Germany
    Rheumatology (Oxford) 44:1525-30. 2005
    ..It is not known whether spinal inflammation remains suppressed over time. Our objective was to assess spinal inflammation by MRI in AS patients after 2 yr of continuous infliximab treatment...
  85. pmc Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis
    J Brandt
    Department of Gastroenterology Rheumatology, Charite, Berlin, Germany
    Ann Rheum Dis 63:1438-44. 2004
    ..To develop and compare candidate improvement criteria for anti-TNFalpha treatment in ankylosing spondylitis with optimal discriminating capacity between treatment and placebo...
  86. pmc Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis
    J Listing
    Deutsches Rheuma ForschungsZentrum, Berlin, Germany
    Ann Rheum Dis 63:1670-2. 2004
    ..To analyse the impact of infliximab treatment on the number of hospital inpatient days and days of sick leave in patients with active ankylosing spondylitis (AS)...
  87. doi request reprint Development of a radiographic scoring tool for ankylosing spondylitis only based on bone formation: addition of the thoracic spine improves sensitivity to change
    X Baraliakos
    Rheumazentrum Ruhrgebiet and Ruhr University Bochum, Herne, Germany
    Arthritis Rheum 61:764-71. 2009
    ..Our objective was to study the contribution of the lower part of the T-spine to structural damage in patients with ankylosing spondylitis (AS)...
  88. ncbi request reprint Classification criteria for rheumatoid arthritis and ankylosing spondylitis
    J Braun
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Clin Exp Rheumatol 27:S68-73. 2009
    ..This is important since early treatment strategies are increasingly and successfully used to treat inflammatory diseases more efficiently...
  89. pmc ASAS/EULAR recommendations for the management of ankylosing spondylitis
    J Zochling
    Rheumazentrum Ruhrgebiet, St Josefs Krankenhaus, Landgrafenstr 15, 44652 Herne, Germany
    Ann Rheum Dis 65:442-52. 2006
    ..To develop evidence based recommendations for the management of ankylosing spondylitis (AS) as a combined effort of the 'ASsessment in AS' international working group and the European League Against Rheumatism...
  90. ncbi request reprint The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab
    F Heldmann
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Clin Exp Rheumatol 29:672-80. 2011
    ..To study the long-term efficacy and safety of treatment with infliximab in patients with ankylosing spondylitis (AS) in a real life setting...
  91. ncbi request reprint [A 46-year-old-patient with granulomatous prostatitis, arthralgia and haemorrhagic rhinitis]
    F Heldmann
    Rheumazentrum Ruhrgebiet, St Josefs Krankenhaus, 44652 Herne
    Dtsch Med Wochenschr 131:22-5. 2006
    ..As the patient had also developed arthralgia and symptoms in the upper respiratory tract, he was admitted to our hospital. The test for c-ANCA with specifity for proteinase 3 was positive. There was no history or symptoms of asthma...
  92. ncbi request reprint [New aspects in the area of spondyloarthritis. Report on the 6(th) International Congress on Spondyloarthropathies]
    U Kiltz
    Rheumazentrum Ruhrgebiet, St Josefs Krankenhaus, Herne
    Z Rheumatol 68:420-2. 2009
    ..These novel aspects have been presented at the 6(th) International Congress on Spondyloarthropathies in Ghent (October, 2(nd) - 4(th) 2008)...
  93. ncbi request reprint Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis
    J Brandt
    Department of Gastroenterology Rheumatology, Charite, Medical University Berlin, Campus Benjamin Franklin, Germany
    Rheumatology (Oxford) 44:342-8. 2005
    ..The objective of the study was to assess the long-term efficacy and safety of etanercept over 1 yr, including discontinuation and readministration...
  94. ncbi request reprint Use of methotrexate in patients with sarcoidosis
    U Kiltz
    Rheumazentrum Ruhrgebiet, Herne, Germany
    Clin Exp Rheumatol 28:S183-5. 2010
    ..In this review we discuss the available literature concerning the treatment of sarcoidosis with methotrexate...
  95. doi request reprint [German patient version of the ASAS/EULAR recommendations for the management of ankylosing spondylitis]
    U Kiltz
    Rheumazentrum Ruhrgebiet, St Josefs Krankenhaus, Herne, Deutschland
    Z Rheumatol 69:171-4, 176-9. 2010
    ..The translation text was approved by the majority in terms of both form and content. Acceptance and circulation of the German patient version should be evaluated in the near future...
  96. ncbi request reprint [Epidemiology and prognostic aspects of ankylosing spondylitis]
    J Braun
    St Josefs Krankenhaus, Rheumazentrum Ruhrgebiet Herne
    Radiologe 44:209-10, 212-6. 2004
    ..Other clinical features such as hip arthritis, early onset of disease, dactylitis, oligoarthritis, limitation of spinal mobility and poor efficacy of nonsteroidal antiinflammatory drugs were found to also have negative prognostic value...